Sanofi making all insulin meds available for $35 a month in US

[The Sanofi-aventis Lantus Glargine Insulin Pen For The Treatment Of Diabetes]
ChandraDhas

* Sanofi (NASDAQ:SNY [https://seekingalpha.com/symbol/SNY]) is expanding a program that will allow all US patients the ability to purchase any of its insulin medications for $35 a month.
* The company's Insulins Valyou Savings Program previously allowed $35 monthly insulin, but only for those without health insurance. With the change, anyone with a prescription, regardless of insurance status, can access the cheaper insulins.
* The expanded eligibility [https://seekingalpha.com/pr/20245706-sanofi-expands-patient-affordability-program-by-offering-access-to-all-its-insulins-for-35] goes into effect on Jan. 1, 2026
* Sanofi's main insulin products include Lantus (insulin glargine), Toujeo (insulin glargine), Apidra (insulin glulisine), and Soliqua (insulin glargine and lixisenatide).
* Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) and Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]), both of whom have large diabetes franchises, have previously instituted $35 a month insulin programs. The Inflation Reduction Act also capped insulin expenses at that amount starting in 2023 for those on Medicare.

MORE ON SANOFI

* Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript [https://seekingalpha.com/article/4825074-sanofi-san-ca-presents-at-bank-of-america-global-healthcare-conference-2025-transcript]
* Historical earnings data for Sanofi [https://seekingalpha.com/symbol/SAN:CA/earnings]
* Financial information for Sanofi [https://seekingalpha.com/symbol/SAN:CA/income-statement]